About Vion

Vion Vision

We are committed to extending the lives and improving the quality of life of cancer patients worldwide by bringing innovative cancer treatments to market.

Incorporated in March 1992 to develop cancer therapies, Vion has been a publicly-traded company since 1995. Vion is now traded on the OTC Bulletin Board and Pink Sheets under the symbol “VION”. Vion has two anticancer compounds in human clinical testing.

Clinical Development

Vion is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our potential product, laromustine (Cloretazine®, VNP40101M) is being evaluated for the treatment of acute myelogenous leukemia (AML) in a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition, three clinical trials of laromustine (Cloretazine®, VNP40101M) are underway in: (i) elderly AML and myelodysplastic syndromes in combination with cytarabine; (ii) brain tumors in combination with temozolomide; and (iii) advanced hematologic malignancies in combination with hematopoietic cell transplantation. Our second potential product, Triapine®, is being evaluated in trials sponsored by the National Cancer Institute.